MedPath

Effects of perioperative propofol infusion on energy expenditure, fat metabolism, protein catabolism and clinical courses following esophageal cancer surgery

Not Applicable
Conditions
Esophageal cancer
Registration Number
JPRN-UMIN000009023
Lead Sponsor
Department of Anesthesiology and Critical Care, Hiroshima University Hospital
Brief Summary

Propofol anesthesia and postoperative propofol sedation resulted in a reduced peak postoperative bladder temperature and lower postoperative C-reactive protein levels than sevoflurane anesthesia followed by midazolam sedation. However, propofol infusion did not show significant effect on energy expenditure, fat metabolism, protein catabolism and clinical courses.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Preoperative exclusion criteria includes the patients who are obese (Body Mass Index > 30), have histories of diabetic mellitus, hyperlipidemia, liver dysfunction, renal dysfunction(Cr > 1.0), high-calorie infusion administration or chemoradiotherapy within 1 month before the day of surgery, or take medications of beta-adrenergic blocking agents, steroid agents or non-steroid anti-inflammatory drugs (NSAIDs). Postoperative exclusion criteria includes the patients who are in need of inspiratory oxygen fraction > 0.6 or positive end-expiratory pressure > 5 cmH2O during mechanical ventilation, dopamine > 3 microgram/kg/min, insulin, diuretic drugs, NSAIDs or beta-adrenergic blocking agents during intensive care unit stay.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome is set to demonstrate that propofol has significant effects on energy expenditure, fat metabolism and protein catabolism.
Secondary Outcome Measures
NameTimeMethod
Secondary outcome includes improvement in postoperative clinical courses by propofol.
© Copyright 2025. All Rights Reserved by MedPath